AMENDMENTS TO CLAIMS

All previous pending claims have been canceled and should be replaced by the newly presented claims presented below.

1-192. (Canceled)

193. (New) An anti-cancer pharmaceutical combination, comprising:

(a) a composition comprising an amount of a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; and

(b) an orally administered composition comprising a 1,3-β glucan having a molecular weight of from about 120,000 Da to about 450,000 Da, in an amount effective to enhance the antibody's anti-tumor effect, and at least one pharmaceutically acceptable carrier;

wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3.

194. (New) The pharmaceutical combination of claim 193 wherein compositions (a) and (b) are administered to the subject concurrently or sequentially.

195. (New) The pharmaceutical combination of claim 193, wherein the antibody is a monoclonal antibody.

196. (New) The pharmaceutical combination of claim 193, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.

197. (New) The pharmaceutical combination of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen EGFR.

198. (New) The pharmaceutical combination of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen GD2.

199. (New) The pharmaceutical combination of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen GD3.

200. (New) The pharmaceutical combination of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen CD20.

201. (New) The pharmaceutical combination of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen HER2.

202. (New) The pharmaceutical combination of claim 193, wherein the cancer cell expressing CD20 is non-Hodgkin's lymphoma, Hodgkin's lymphoma, or Epstein-Barr related lymphoma.

203. (New) The pharmaceutical combination of claim 202, wherein the lymphoma is non-Hodgkin's lymphoma.

204. (New) The pharmaceutical combination of claim 197, wherein the cancer cell expressing the EGFR is an epidermoid cancer cell.

205. (New) The pharmaceutical combination of claim 198, wherein the cancer cell expressing the antigen GD2 is a neuroblastoma.

206. (New) The pharmaceutical combination of claim 199, wherein the cancer cell expressing the antigen GD3 is a melanoma cancer cell.

207. (New) The pharmaceutical combination of claim 201, wherein the cancer cell expressing the antigen HER2 is a breast cancer cell.

208. (New) The pharmaceutical combination of claim 193, wherein the 1,3-β glucan has a molecular weight from about 180,000 Daltons to about 450,000 Daltons.

209. (New) The pharmaceutical combination of claim 208, wherein the 1,3-β glucan has a molecular weight up to about 360,000 Daltons.

210. (New) The pharmaceutical combination of claim 193, wherein the 1,3-β glucan has a molecular weight from about 250,000 Daltons to about 450,000 Daltons.

211. (New) The pharmaceutical combination of claim 193, wherein the 1,3-β glucan is obtained from barley, oat, wheat, moss or yeast.

212. (New) The pharmaceutical combination of claim 193, wherein the amount of the orally administered 1,3-β glucan is about >= 25 mg/kg/day, five days a week for a total of 2-4 weeks.

213. (New) The pharmaceutical combination of claim 193, wherein the 1,3-β glucan further comprises 1,4-β linkages in its backbone.

214. (New) The pharmaceutical combination of claim 193, wherein the glucan further comprises at least one side chain.

215. (New) The pharmaceutical combination of claim 214, wherein the at least one side chain is linked to the backbone by a 1,6-β linkage.

216. (New) The pharmaceutical combination of claim 193, wherein the orally administered composition comprising a 1,3-β glucan has a viscosity of greater than about 5.6 cSt and up to about 100 cSt.

217. (New) The pharmaceutical combination of claim 216, wherein the viscosity is from about 20 cSt to about 100 cSt.

218. (New) The pharmaceutical combination of claim 216, wherein the viscosity is from about 30 cSt to about 69 cSt.

219. (New) An anti-cancer pharmaceutical combination, comprising, comprising:

(a) a composition comprising an amount of a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; an

(b) an orally administered composition comprising a 1,3-β glucan having a molecular weight of from about 120,000 Da to about 450,000 Da, in an amount effective to enhance the antibody's anti-tumor effect, and at least one pharmaceutically acceptable carrier;

wherein the cancer cell is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma.

220. (New) The pharmaceutical combination of claim 219, wherein compositions (a) and (b) are administered to the subject concurrently or sequentially.

221. (New) The pharmaceutical combination of claim 219, wherein the antibody is a monoclonal antibody.

222. (New) The pharmaceutical combination of claim 219, wherein the antibody is further capable of

activating an antibody dependent cell-mediated cytotoxicity response.

223. (New) The pharmaceutical combination of claim 219, wherein the antibody is directed to the EGFR(epidermal growth factor receptor).

224. (New) The pharmaceutical combination of claim 219, wherein the antibody is directed to antigen GD2.

225. ((New) The pharmaceutical combination of claim 219, wherein the antibody is directed to antigen GD3.

226. (New) The pharmaceutical combination of claim 219, wherein the antibody binds to the antigen CD20.

227. (New) The pharmaceutical combination of claim 219, wherein the antibody binds to the antigen HER2.

228. (New) The pharmaceutical combination of claim 219, wherein the glucan is isolated from barley, oat, wheat, moss or yeast.

229. (New) The pharmaceutical combination of claim 219, wherein the 1,3-β glucan further comprises 1,4-β linkages in its backbone.

230. (New) The pharmaceutical combination of claim 219, wherein the 1,3-β glucan further comprises at least one side chain linked to the backbone.

231. (New) The pharmaceutical combination of claim 230, wherein the at least one side chain is linked to the backbone by a 1,6-β linkage.

232. (New) The pharmaceutical combination of claim 219, wherein the amount of the orally administered β glucan is about >= 25 mg/kg/day, five days a week for a total of 2-4 weeks.

233. (New) The pharmaceutical combination of claim 219, wherein the 1,3-β glucan has a molecular weight from about 180,000 Daltons to about 450,000 Daltons.

234. (New) The pharmaceutical combination of claim 208, wherein the 1,3-β glucan has a molecular weight up to about 360,000 Daltons.

235. (New) The pharmaceutical combination of claim 219, wherein the 1,3-β glucan has a molecular weight from about 250,000 Daltons to about 450,000 Daltons.

236. (New) The pharmaceutical combination of claim 219, wherein the orally administered composition comprising a 1,3-β glucan has a viscosity of greater than about 5.6 cSt and up to about 100 cSt.

237. (New) The pharmaceutical combination of claim 237, wherein the viscosity is from about 20 cSt to about 100 cSt.

238. (New) The pharmaceutical combination of claim 237, wherein the viscosity is from about 30 cSt to about 69 cSt.